Kidney Disease

Your daily dose of the clinical news you may have missed.

Results from a new study of Medicare beneficiaries admitted for an emergency general surgery show the odds of 30-day readmission was 67% lower for those with follow-up visit.

Empagliflozin is approved to lower the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression.

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.

A daily dose of clinical news on Patient Care you may have missed.

Among persons with hypertension and T2D with albuminuria, nearly two-thirds currently go undetected, a significant barrier to diagnosis and treatment of CKD.

Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.

KidneyIntelX.dkd, a first-in-class AI-enabled prognostic test, stratifies risk of DKD progression in 5 years and is specific for early stage disease.

Your daily dose of clinical news you may have missed.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.

Your daily dose of clinical news you may have missed.

Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.

The patient is in her mid-20s and other than an intermittent mild headache she denies any other pain and has no fever. Can you Dx based on the CT?

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

Drs Aide Vega and Fernando Carnavali highlight the increased control in both diabetes and kidney function with the use of KidneyIntelX in patients with DKD.

Aida Vega, MD, and Fernando Carnavali, MD, discuss the KidneyIntelX study and the rates of referrals of high-risk DKD patients to specialist care.

Aida Vega, MD, and Fernando Carnavali, MD, review the population characteristics of a study involving the use of KidneyIntelX in DKD.

Experts in diabetic nephropathy present a study of the use of the KidneyIntelX test in patients with DKD.

Experts review the role of the urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in current DKD progression screening practices.

Aida Vega, MD, and Fernando Carnavali, MD, discuss the limitations of the tools available to clinicians to screen for DKD, such as Kidney Disease: Improving Global Outcomes (KDIGO).

Fernando Carnavali, MD, comments on the prevalence of diabetic kidney disease (DKD) in the United States, the financial burden on patients and the healthcare system, as well as the importance of early detection of kidney disease in patients with diabetes.

ACC 2023. Type 2 diabetes and CKD in patients with CVD are mutually independent predictors of MACE, concluded authors of a new study.

Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

In a study of nearly 100 adults with CKD stages G3b-4 and medical comorbidity, a 12-month exercise program was found safe and improved physical functioning.

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.